Loading…
Chemoprevention of Benzo(a)pyrene-induced Lung Tumors in Mice by the Farnesyltransferase Inhibitor R115777
Purpose: Inhibitors of farnesyltransferase ( e.g., R115777) are being developed for therapy and prevention of various cancers. The efficacy of R115777 [Zarnestra; ( B )-6-[amino(4-chlorophenyl)(1-methyl-1 H -imidazol-5-yl)-methyl]-4-(3-chlorophenyl)-1-methyl-2(1 H )-quinolinone] to prevent the devel...
Saved in:
Published in: | Clinical cancer research 2003-05, Vol.9 (5), p.1927-1930 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 1930 |
container_issue | 5 |
container_start_page | 1927 |
container_title | Clinical cancer research |
container_volume | 9 |
creator | GUNNING, William T KRAMER, Paula M LUBET, Ronald A STEELE, Vernon E END, David W WOUTERS, Walter PEREIRA, Michael A |
description | Purpose: Inhibitors of farnesyltransferase
( e.g., R115777) are being developed for therapy and
prevention of various cancers. The efficacy of R115777 [Zarnestra;
( B )-6-[amino(4-chlorophenyl)(1-methyl-1 H -imidazol-5-yl)-methyl]-4-(3-chlorophenyl)-1-methyl-2(1 H )-quinolinone]
to prevent the development of lung tumors in mice was determined.
Experimental Design: Female strain A mice (7–8 weeks of
age) were given 100 mg/kg benzo( a )pyrene [B(a)P] by
i.p. injection, and 4 or 14 weeks later, they were given 50 or 100
mg/kg R115777 by oral gavage 5 days/week. The mice were sacrificed 22
weeks after they received the B(a)P.
Results : Tumor multiplicity was 5.0 ± 0.85,
4.5 ± 0.52, 2.1 ± 0.31, and 1.5 ± 0.31 tumors/mouse
in mice that received 0, 50, 100 (weeks 4–22), or 100 (weeks 14–22)
mg/kg R115777. Thus, 100 mg/kg R115777 was similarly effective in
preventing lung tumors when administered during the promotional phase
of carcinogenesis [that is, either 4 or 14 weeks after B(a)P],
whereas the lower dose of 50 mg/kg R115777 was ineffective. The
proliferating cell nuclear antigen labeling index was also
significantly reduced in lung tumors from mice treated with 100 mg/kg
R115777 starting at 4 or 14 weeks.
Conclusions: These results demonstrated that R115777 can
prevent the development of lung tumors in the A/J mouse model, where
tumors routinely have mutations in the Ki- Ras oncogene. |
format | article |
fullrecord | <record><control><sourceid>pubmed_pasca</sourceid><recordid>TN_cdi_pubmed_primary_12738751</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>12738751</sourcerecordid><originalsourceid>FETCH-LOGICAL-h269t-13c78e99ef3d401731dcc06e5a06f877a265d354ce0087362ca068e83152922e3</originalsourceid><addsrcrecordid>eNpFz11LwzAUBuAiipvTvyC5EfWikI-mSS51bDqYCDKvS5aerhlrWpJWqb_ewCZenQPn4eW8Z8mUcC5SRnN-HncsZIozRifJVQh7jElGcHaZTAgVTApOpsl-XkPTdh6-wPW2dait0DO4n_ZBP3ajBwepdeVgoETrwe3QZmhaH5B16M0aQNsR9TWgpfYOwnjovXahAq8DoJWr7db2rUcfhHAhxHVyUelDgJvTnCWfy8Vm_pqu319W86d1WtNc9SlhRkhQCipWZpgIRkpjcA5c47ySQujYrWQ8M4CxFCynJh4kSEY4VZQCmyW3x9xu2DZQFp23jfZj8Vc6grsT0MHoQxWfNjb8u0wopqiM7v7oarurv62HwkQJ3kMA7U1dqIIXRMXYX1Uubhk</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Chemoprevention of Benzo(a)pyrene-induced Lung Tumors in Mice by the Farnesyltransferase Inhibitor R115777</title><source>Freely Accessible Journals</source><creator>GUNNING, William T ; KRAMER, Paula M ; LUBET, Ronald A ; STEELE, Vernon E ; END, David W ; WOUTERS, Walter ; PEREIRA, Michael A</creator><creatorcontrib>GUNNING, William T ; KRAMER, Paula M ; LUBET, Ronald A ; STEELE, Vernon E ; END, David W ; WOUTERS, Walter ; PEREIRA, Michael A</creatorcontrib><description>Purpose: Inhibitors of farnesyltransferase
( e.g., R115777) are being developed for therapy and
prevention of various cancers. The efficacy of R115777 [Zarnestra;
( B )-6-[amino(4-chlorophenyl)(1-methyl-1 H -imidazol-5-yl)-methyl]-4-(3-chlorophenyl)-1-methyl-2(1 H )-quinolinone]
to prevent the development of lung tumors in mice was determined.
Experimental Design: Female strain A mice (7–8 weeks of
age) were given 100 mg/kg benzo( a )pyrene [B(a)P] by
i.p. injection, and 4 or 14 weeks later, they were given 50 or 100
mg/kg R115777 by oral gavage 5 days/week. The mice were sacrificed 22
weeks after they received the B(a)P.
Results : Tumor multiplicity was 5.0 ± 0.85,
4.5 ± 0.52, 2.1 ± 0.31, and 1.5 ± 0.31 tumors/mouse
in mice that received 0, 50, 100 (weeks 4–22), or 100 (weeks 14–22)
mg/kg R115777. Thus, 100 mg/kg R115777 was similarly effective in
preventing lung tumors when administered during the promotional phase
of carcinogenesis [that is, either 4 or 14 weeks after B(a)P],
whereas the lower dose of 50 mg/kg R115777 was ineffective. The
proliferating cell nuclear antigen labeling index was also
significantly reduced in lung tumors from mice treated with 100 mg/kg
R115777 starting at 4 or 14 weeks.
Conclusions: These results demonstrated that R115777 can
prevent the development of lung tumors in the A/J mouse model, where
tumors routinely have mutations in the Ki- Ras oncogene.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>PMID: 12738751</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Alkyl and Aryl Transferases - antagonists & inhibitors ; Animals ; Antineoplastic Agents - therapeutic use ; Benzo(a)pyrene - toxicity ; Biological and medical sciences ; Carcinogenesis, carcinogens and anticarcinogens ; Chemical agents ; Chemoprevention ; Enzyme Inhibitors - therapeutic use ; Female ; Lung Neoplasms - chemically induced ; Lung Neoplasms - prevention & control ; Medical sciences ; Mice ; Mice, Inbred A ; Quinolones - therapeutic use ; Tumors</subject><ispartof>Clinical cancer research, 2003-05, Vol.9 (5), p.1927-1930</ispartof><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14793928$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12738751$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>GUNNING, William T</creatorcontrib><creatorcontrib>KRAMER, Paula M</creatorcontrib><creatorcontrib>LUBET, Ronald A</creatorcontrib><creatorcontrib>STEELE, Vernon E</creatorcontrib><creatorcontrib>END, David W</creatorcontrib><creatorcontrib>WOUTERS, Walter</creatorcontrib><creatorcontrib>PEREIRA, Michael A</creatorcontrib><title>Chemoprevention of Benzo(a)pyrene-induced Lung Tumors in Mice by the Farnesyltransferase Inhibitor R115777</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>Purpose: Inhibitors of farnesyltransferase
( e.g., R115777) are being developed for therapy and
prevention of various cancers. The efficacy of R115777 [Zarnestra;
( B )-6-[amino(4-chlorophenyl)(1-methyl-1 H -imidazol-5-yl)-methyl]-4-(3-chlorophenyl)-1-methyl-2(1 H )-quinolinone]
to prevent the development of lung tumors in mice was determined.
Experimental Design: Female strain A mice (7–8 weeks of
age) were given 100 mg/kg benzo( a )pyrene [B(a)P] by
i.p. injection, and 4 or 14 weeks later, they were given 50 or 100
mg/kg R115777 by oral gavage 5 days/week. The mice were sacrificed 22
weeks after they received the B(a)P.
Results : Tumor multiplicity was 5.0 ± 0.85,
4.5 ± 0.52, 2.1 ± 0.31, and 1.5 ± 0.31 tumors/mouse
in mice that received 0, 50, 100 (weeks 4–22), or 100 (weeks 14–22)
mg/kg R115777. Thus, 100 mg/kg R115777 was similarly effective in
preventing lung tumors when administered during the promotional phase
of carcinogenesis [that is, either 4 or 14 weeks after B(a)P],
whereas the lower dose of 50 mg/kg R115777 was ineffective. The
proliferating cell nuclear antigen labeling index was also
significantly reduced in lung tumors from mice treated with 100 mg/kg
R115777 starting at 4 or 14 weeks.
Conclusions: These results demonstrated that R115777 can
prevent the development of lung tumors in the A/J mouse model, where
tumors routinely have mutations in the Ki- Ras oncogene.</description><subject>Alkyl and Aryl Transferases - antagonists & inhibitors</subject><subject>Animals</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Benzo(a)pyrene - toxicity</subject><subject>Biological and medical sciences</subject><subject>Carcinogenesis, carcinogens and anticarcinogens</subject><subject>Chemical agents</subject><subject>Chemoprevention</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Female</subject><subject>Lung Neoplasms - chemically induced</subject><subject>Lung Neoplasms - prevention & control</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred A</subject><subject>Quinolones - therapeutic use</subject><subject>Tumors</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNpFz11LwzAUBuAiipvTvyC5EfWikI-mSS51bDqYCDKvS5aerhlrWpJWqb_ewCZenQPn4eW8Z8mUcC5SRnN-HncsZIozRifJVQh7jElGcHaZTAgVTApOpsl-XkPTdh6-wPW2dait0DO4n_ZBP3ajBwepdeVgoETrwe3QZmhaH5B16M0aQNsR9TWgpfYOwnjovXahAq8DoJWr7db2rUcfhHAhxHVyUelDgJvTnCWfy8Vm_pqu319W86d1WtNc9SlhRkhQCipWZpgIRkpjcA5c47ySQujYrWQ8M4CxFCynJh4kSEY4VZQCmyW3x9xu2DZQFp23jfZj8Vc6grsT0MHoQxWfNjb8u0wopqiM7v7oarurv62HwkQJ3kMA7U1dqIIXRMXYX1Uubhk</recordid><startdate>20030501</startdate><enddate>20030501</enddate><creator>GUNNING, William T</creator><creator>KRAMER, Paula M</creator><creator>LUBET, Ronald A</creator><creator>STEELE, Vernon E</creator><creator>END, David W</creator><creator>WOUTERS, Walter</creator><creator>PEREIRA, Michael A</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20030501</creationdate><title>Chemoprevention of Benzo(a)pyrene-induced Lung Tumors in Mice by the Farnesyltransferase Inhibitor R115777</title><author>GUNNING, William T ; KRAMER, Paula M ; LUBET, Ronald A ; STEELE, Vernon E ; END, David W ; WOUTERS, Walter ; PEREIRA, Michael A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h269t-13c78e99ef3d401731dcc06e5a06f877a265d354ce0087362ca068e83152922e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Alkyl and Aryl Transferases - antagonists & inhibitors</topic><topic>Animals</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Benzo(a)pyrene - toxicity</topic><topic>Biological and medical sciences</topic><topic>Carcinogenesis, carcinogens and anticarcinogens</topic><topic>Chemical agents</topic><topic>Chemoprevention</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Female</topic><topic>Lung Neoplasms - chemically induced</topic><topic>Lung Neoplasms - prevention & control</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred A</topic><topic>Quinolones - therapeutic use</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GUNNING, William T</creatorcontrib><creatorcontrib>KRAMER, Paula M</creatorcontrib><creatorcontrib>LUBET, Ronald A</creatorcontrib><creatorcontrib>STEELE, Vernon E</creatorcontrib><creatorcontrib>END, David W</creatorcontrib><creatorcontrib>WOUTERS, Walter</creatorcontrib><creatorcontrib>PEREIRA, Michael A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GUNNING, William T</au><au>KRAMER, Paula M</au><au>LUBET, Ronald A</au><au>STEELE, Vernon E</au><au>END, David W</au><au>WOUTERS, Walter</au><au>PEREIRA, Michael A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chemoprevention of Benzo(a)pyrene-induced Lung Tumors in Mice by the Farnesyltransferase Inhibitor R115777</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2003-05-01</date><risdate>2003</risdate><volume>9</volume><issue>5</issue><spage>1927</spage><epage>1930</epage><pages>1927-1930</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>Purpose: Inhibitors of farnesyltransferase
( e.g., R115777) are being developed for therapy and
prevention of various cancers. The efficacy of R115777 [Zarnestra;
( B )-6-[amino(4-chlorophenyl)(1-methyl-1 H -imidazol-5-yl)-methyl]-4-(3-chlorophenyl)-1-methyl-2(1 H )-quinolinone]
to prevent the development of lung tumors in mice was determined.
Experimental Design: Female strain A mice (7–8 weeks of
age) were given 100 mg/kg benzo( a )pyrene [B(a)P] by
i.p. injection, and 4 or 14 weeks later, they were given 50 or 100
mg/kg R115777 by oral gavage 5 days/week. The mice were sacrificed 22
weeks after they received the B(a)P.
Results : Tumor multiplicity was 5.0 ± 0.85,
4.5 ± 0.52, 2.1 ± 0.31, and 1.5 ± 0.31 tumors/mouse
in mice that received 0, 50, 100 (weeks 4–22), or 100 (weeks 14–22)
mg/kg R115777. Thus, 100 mg/kg R115777 was similarly effective in
preventing lung tumors when administered during the promotional phase
of carcinogenesis [that is, either 4 or 14 weeks after B(a)P],
whereas the lower dose of 50 mg/kg R115777 was ineffective. The
proliferating cell nuclear antigen labeling index was also
significantly reduced in lung tumors from mice treated with 100 mg/kg
R115777 starting at 4 or 14 weeks.
Conclusions: These results demonstrated that R115777 can
prevent the development of lung tumors in the A/J mouse model, where
tumors routinely have mutations in the Ki- Ras oncogene.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>12738751</pmid><tpages>4</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1078-0432 |
ispartof | Clinical cancer research, 2003-05, Vol.9 (5), p.1927-1930 |
issn | 1078-0432 1557-3265 |
language | eng |
recordid | cdi_pubmed_primary_12738751 |
source | Freely Accessible Journals |
subjects | Alkyl and Aryl Transferases - antagonists & inhibitors Animals Antineoplastic Agents - therapeutic use Benzo(a)pyrene - toxicity Biological and medical sciences Carcinogenesis, carcinogens and anticarcinogens Chemical agents Chemoprevention Enzyme Inhibitors - therapeutic use Female Lung Neoplasms - chemically induced Lung Neoplasms - prevention & control Medical sciences Mice Mice, Inbred A Quinolones - therapeutic use Tumors |
title | Chemoprevention of Benzo(a)pyrene-induced Lung Tumors in Mice by the Farnesyltransferase Inhibitor R115777 |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T13%3A14%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chemoprevention%20of%20Benzo(a)pyrene-induced%20Lung%20Tumors%20in%20Mice%20by%20the%20Farnesyltransferase%20Inhibitor%20R115777&rft.jtitle=Clinical%20cancer%20research&rft.au=GUNNING,%20William%20T&rft.date=2003-05-01&rft.volume=9&rft.issue=5&rft.spage=1927&rft.epage=1930&rft.pages=1927-1930&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/&rft_dat=%3Cpubmed_pasca%3E12738751%3C/pubmed_pasca%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-h269t-13c78e99ef3d401731dcc06e5a06f877a265d354ce0087362ca068e83152922e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/12738751&rfr_iscdi=true |